Article

Predictive Factors of Response to Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs): A Multi-Institutional Study

2019-06-05

Abstract excerpt

Imatinib 400 mg is the standard of care for medical treatment of advanced GISTs. In the majority of cases, however, GISTs eventually develop resistance to imatinib. The optimal second line treatment has not been established yet and imatinib dose escalation (800 mg) or sunitinib represent two feasible options. The objective of this retrospective, multi-institutional, study is to analyze the validity of several para...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 724d68ff-bde8-57f9-9bdb-5584c4350647
DOI: 10.20944/preprints201906.0033.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Predictive Factors of Response to Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs): A Multi-Institutional StudyDOI 10.20944/preprints201906.0033.v1Read

Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Semantic proximity Read

Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.Semantic proximity Read

Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.Semantic proximity Read

Gastrointestinal stromal tumors (GISTs): from science to targeted therapy.Semantic proximity Read

[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].Semantic proximity Read

Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read

Optimal use of targeted agents for advanced gastrointestinal stromal tumours.Semantic proximity Read

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.Semantic proximity Read

Gastrointestinal stromal tumors, version 2.2014.Semantic proximity Read

Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.Semantic proximity Read

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.Semantic proximity Read

The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.Semantic proximity Read